Reseachers from WEHI (Melbourne, Australia) have found a new way to predict a subset of patients who are likely to become ...
DNA synthesis platform developer joins de novo designer in latest of three partnerships recently launched or advanced.
A pioneering DNA test is being rolled out on the NHS as experts say there is a one in four chance of another pandemic on the scale of Covid-19 in the next decade ...
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
The executive in charge of AstraZeneca operations in China is under detention by Chinese authorities who are investigating employees there, the company said. The disclosure comes after AstraZeneca ...
Q3 revenue and core EPS beat estimates AstraZeneca announces $3.5 billion US investment CEO says growth looks set to continue through 2025 Shares down as market focuses on co's China issues ...
Over the past three years, additional insurance fraud cases have emerged involving AstraZeneca employees in various Chinese regions. The investigation focuses on potential breaches of data privacy ...
Not too long ago, pharmaceutical giant Astrazeneca reached a £200bn valuation—one of only a few London-listed FTSE 100 companies to do so. The major milestone was a testament to CEO Pascal ...
AstraZeneca Plc said its experimental obesity pill was well tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines. The ...
Nov 5 (Reuters) - AstraZeneca (AZN.L), opens new tab shares on Tuesday recorded their worst day since March 2020 after a report that dozens of the drugmaker's senior executives in China could be ...
AstraZeneca Says Current, Former Executives Involved in China Probe The company’s China president has been detained by authorities Astra has attempted to quell concerns over the investigation ...
A senior AstraZeneca AZN0.05%increase; green up pointing triangle executive is under detention by Chinese authorities investigating the pharmaceutical company’s employees in the country.